Inogen

Inogen, Inc. engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products include Inogen One G4 system, Inogen One G3 system, Inogen One G5 system, Inogen TAV, and Inogen at Home. The company was founded by Alison Perry, Alison K. Bauerlein, Brenton Taylor, and Byron Myers on November 27, 2001 and is headquartered in Goleta, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inogen reports revenue growth amidst challenges, eyes positive EBITDA

Inogen reported revenue growth in Q4 2022 despite challenges and aims for positive adjusted EBITDA by Q4 2023. The company successfully managed supply chain challenges and plans new product launches in 2023.
While facing challenges in DTC evolution and gross margin decline, Inogen sees promising market opportunities for sustainable growth. The company's strategic decisions to secure supply assurance and focus on innovation position it for future success.
With a focus on addressing challenges, leveraging strengths, and capitalizing on opportunities, Inogen is poised for growth and profitability in 2023. The company's commitment to managing disruptions and driving commercial strategy reflects a positive outlook for the future.

Inogen reports Q1 performance meeting expectations, eyes profitability by Q4

Inogen's Q1 2023 performance was mixed, with revenue meeting expectations but facing challenges in certain sales segments.
The company's strategic focus on patient-centric models and product expansion positions it well for future growth.
With a clear roadmap to profitability by Q4 2023 and a strong financial position, Inogen remains optimistic about its outlook.

Inogen reports Q2 revenue shortfall, focuses on strategic growth

Inogen faced challenges in Q2 2023 but is focused on strategic initiatives to drive growth and regain lost business.
The company's financial results were impacted by supply chain constraints, aggressive pricing tactics, and restructuring charges.
Opportunities for growth exist through international expansion, product enhancements, and entering new market segments.
Management's emphasis on commercial execution and innovation highlights a commitment to sustainable growth.

Inogen reports Q3 revenue decline, eyes international growth opportunities

Inogen faced revenue declines in Q3 2023, driven by challenges in direct-to-consumer and domestic B2B sales.
Despite these setbacks, the company showed strength in international B2B and rental revenue growth.
Operational efficiency improvements and strategic cost controls are crucial for addressing margin pressures and financial performance.
The acquisition of Physio-Assist underscores Inogen's commitment to expanding its product portfolio and enhancing market competitiveness.

Inogen reports $316M full-year revenue, eyes growth amid challenges

Inogen's Q4 2023 earnings call highlighted achievements, challenges, and opportunities. The company aims to drive growth through strategic priorities, innovation, and market leadership. Despite facing challenges in revenue and net loss, Inogen is focused on improving performance and capitalizing on market opportunities.

Inogen reports solid Q1 earnings, eyes growth amid market challenges

Inogen's Q1 2024 performance reflects steady revenue growth, improved gross margins, and prudent cost management. The company's strategic priorities, strong financial position, and revenue guidance for Q2 2024 signal resilience and growth potential amidst market challenges and opportunities.

Inogen reports Q2 revenue growth and profitability amidst operational challenges

Inogen's Q2 2024 performance showed revenue growth, improved gross margin, and achieved adjusted EBITDA profitability.
While facing challenges like increased operating expenses and DTC sales decline, the company is focused on sustainable profitability.
Opportunities lie in channel-specific strategies, innovation pipeline expansion, and long-term growth investments.

Inogen reports $89M Q3 revenue with improved profitability and strategic growth

Inogen delivered solid Q3 performance with revenue growth and profitability. Faces challenges in direct-to-consumer sales and net loss. Opportunities lie in improving sales force efficiency and expanding market reach. Strong financial position for future growth initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inogen, Inc. is a medical technology company, which engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products include Inogen One G4 system, Inogen One G3 system, Inogen One G5 system, Inogen TAV, and Inogen at Home. The company was founded by Alison Perry, Alison K. Bauerlein, Brenton Taylor, and Byron Myers on November 27, 2001 and is headquartered in Goleta, CA.

Inogen (INGN) reported earnings 30 days ago. What's next for the stock?

Inogen (INGN) Down 11.5% Since Last Earnings Report: Can It Rebound?

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that Elizabeth (Beth) Mora has been appointed to its Board of Directors, effective May 24, 2021. In addition, Ms. Mora was appointed as a member of the Board's Audit Committee. She will serve as a Class I director, with a term expiring at the annual meeting of stockholders to be held in 2024. Ms. Mora fills the vacan

Inogen Strengthens Board of Directors with Addition of Elizabeth Mora

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Company's management will be participating in the 41st Annual William Blair Virtual Growth Stock Conference. Inogen's President and CEO, Nabil Shabshab, and CFO, Alison Bauerlein, are scheduled to present on Thursday, June 3rd, 2021 at 4:00 p.m. CDT. Interested parties can access the webcast from the News /

Inogen Announces Participation in the 41st Annual William Blair Virtual Growth Stock Conference

Inogen (INGN) gains traction from revenue growth within its Rental segment in Q1.

Inogen (INGN) Q1 Loss Narrower Than Expected, Revenues Beat

Inogen, Inc. (INGN) CEO Nabil Shabshab on Q1 2021 Results - Earnings Call Transcript

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three months ended March 31, 2021. First Quarter 2021 Highlights Total revenue of $86.9 million, down 1.8% from the same period in 2020, primarily due to the impacts of the COVID-19 pandemic Domestic business-to-business revenue of $30.7 million, up 11.6% from the same period in 2020 Rental r

Inogen Announces First Quarter 2021 Financial Results

Owens & Minor

DENTSPLY SIRONA

Rebound in base sales make us optimistic about OMI, INGN, XRAY and CNTG's results this time around.

4 Medical Products Stocks Set to Beat This Earnings Season

Inogen (NASDAQ:INGN) unveils its next round of earnings this Tuesday, May 04. Get prepared with Benzinga's ultimate preview for Inogen's Q1 earnings.

Inogen's Earnings Outlook

As of late, it has definitely been a great time to be an investor in Inogen, Inc. (INGN).

Inogen's (INGN) Shares March Higher, Can It Continue?

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release first quarter 2021 financial results after market close on Tuesday, May 4th, 2021. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET. Individuals interested in listening to the conference call may do so by dialing (877) 841-3961 for domestic callers or (201) 689-858

Inogen to Announce First Quarter 2021 Financial Results on May 4th, 2021

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that its Board of Directors has appointed George Parr as Inogen's Executive Vice President and Chief Commercial Officer, effective April 12, 2021. On April 2, 2021 and April 5, 2021, respectively, Byron Myers, Executive Vice President, Marketing, and Arron Retterer, Executive Vice President, Sales, announced that the

Inogen Announces Appointment of Chief Commercial Officer, Transition of Certain Officers, and Preliminary, Unaudited First Quarter 2021 Revenue Range

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Company's management will be participating in the 20th Annual Needham Virtual Healthcare Conference. Inogen's President and CEO, Nabil Shabshab, and CFO, Alison Bauerlein, are scheduled to present on Monday, April 12th, 2021 at 10:15 a.m. ET. Interested parties can access the webcast from the News / Events s

Inogen Announces Participation in the 20th Annual Needham Virtual Healthcare Conference

Why Is Inogen (INGN) Down 9.4% Since Last Earnings Report?

Inogen's (INGN) fourth-quarter results benefit from higher rental revenues and strength in business-to-business revenues.

Inogen (INGN) Q4 Earnings and Revenues Surpass Estimates

Inogen's (INGN) CEO Nabil Shabshab on Q4 2020 Results - Earnings Call Transcript

Inogen (INGN) delivered earnings and revenue surprises of 17.86% and 6.92%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Inogen (INGN) Reports Q4 Loss, Tops Revenue Estimates

Shares of Inogen (NASDAQ:INGN) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 483.33% year over year to ($0.23), which beat the estimate of ($0.26).

Recap: Inogen Q4 Earnings

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three- and twelve-month periods ended December 31, 2020. Fourth Quarter 2020 Highlights Total revenue of $74.0 million, down 6.3% from the same period in 2019, primarily due to the impacts of the COVID-19 pandemic Domestic business-to-business sales of $24.2 million, up 17.9% from the same pe

Inogen Announces Fourth Quarter 2020 Financial Results

Inogen (NASDAQ:INGN) announces its next round of earnings this Wednesday, February 24. Here is Benzinga's everything-that-matters guide for this Wednesday's Q4 earnings announcement.

Earnings Outlook For Inogen

Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Inogen (INGN) to Report a Decline in Earnings: What to Look Out for

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that Kristen Miranda has been appointed to its Board of Directors, effective March 1, 2021. In addition, Ms. Miranda was appointed to the Board's Compensation Committee. She will serve as a Class I director, with a term expiring at the annual meeting of stockholders to be held in 2021. Ms. Miranda fills the vacancy o

Inogen Strengthens Board of Directors with Addition of Kristen Miranda

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Company's management will be participating in the 10th Annual SVB Leerink Healthcare Conference. Inogen's President and CEO, Nabil Shabshab, and CFO, Alison Bauerlein, are scheduled to present on Thursday, February 25th, 2021 at 2:20 p.m. ET. Interested parties can access the webcast from the News / Events s

Inogen Announces Participation in the 10th Annual SVB Leerink Global Healthcare Conference

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release fourth quarter and year end 2020 financial results after market close on Wednesday, February 24th, 2021. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET. Individuals interested in listening to the conference call may do so by dialing (877) 841-3961 for domestic ca

Inogen to Announce Fourth Quarter and Year End 2020 Financial Results on February 24th, 2021

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that its Board of Directors has appointed Nabil Shabshab as Inogen's President and Chief Executive Officer (“CEO”), effective February 8, 2021. In addition, Mr. Shabshab was appointed to the Board of Directors, effective February 8, 2021. Mr. Shabshab will succeed Scott Wilkinson, who is retiring as President, CEO, a

Inogen Announces CEO Transition

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Company's management will be participating in the 39th Annual J.P. Morgan Healthcare Conference. Inogen's President and CEO, Scott Wilkinson, and CFO, Alison Bauerlein, are scheduled to present on Tuesday, January 12th, 2021 at 5:20 p.m. EST. Interested parties can access the live audio webcast from the News

News for Inogen Stock (INGN)